Elevated serum levels of pigment epithelium-derived factor in the metabolic syndrome

被引:194
作者
Yamagishi, Sho-ichi
Adachi, Hisashi
Abe, Akio
Yashiro, Takako
Enomoto, Mika
Furuki, Kumiko
Hino, Asuka
Jinnouchi, Yuko
Takenaka, Katsuhiko
Matsui, Takanori
Nakamura, Kazuo
Imaizumi, Tsutomu
机构
[1] Kurume Univ, Dept Internal Med 3, Sch Med, Kurume, Fukuoka 8300011, Japan
[2] SRL Inc, Cytokine Sect, Kanagawa 2291125, Japan
关键词
D O I
10.1210/jc.2005-2654
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: Pigment epithelium-derived factor (PEDF), a potent inhibitor of angiogenesis with neuronal differentiating activity, inhibits endothelial cell injury in vitro, thus suggesting the involvement of PEDF in atherosclerosis. Therefore, elucidating the relationship between serum levels of PEDF and coronary risk factors could provide a clue to understanding the pathophysiological role of PEDF in vivo. Objective: We examined whether serum levels of PEDF were associated with risk factors for coronary artery disease. Design: The study was designed as a cross-sectional study. Setting: The study was set within the general community. Patients or Other Participants: A total of 196 general Japanese residents (age 65.7 +/- 9.3 yr; 71 males and 125 females) without clinical evidence of coronary or peripheral arterial occlusive diseases were enrolled in this study. Results: PEDF showed a normal distribution, ranging from 8 - 24 mu g/ml, with a mean of 14.6 +/- 3.2 mu g/ml. Multivariate analyses revealed that uric acid (P < 0.001), waist circumference (P = 0.009), insulin (P = 0.019), and triglycerides (P = 0.028) were significant independent determinants of serum PEDF levels. Age- and uric acid-adjusted PEDF levels were significantly higher (P = 0.048 for men and P = 0.007 for women) in proportion to the accumulation of the number of the components of the metabolic syndrome. Conclusions: The present study reveals that serum levels of PEDF are strongly associated with the metabolic syndrome. Our results suggest that serum PEDF levels may be elevated as a counter-system in the metabolic syndrome.
引用
收藏
页码:2447 / 2450
页数:4
相关论文
共 17 条
[1]   The prospective association between adiponectin and coronary artery disease among individuals with type 1 diabetes. The Pittsburgh Epidemiology of Diabetes Complications Study [J].
Costacou, T ;
Zgibor, JC ;
Evans, RW ;
Otvos, J ;
Lopes-Virella, MF ;
Tracy, RP ;
Orchard, TJ .
DIABETOLOGIA, 2005, 48 (01) :41-48
[2]   Pigment epithelium-derived factor: A potent inhibitor of angiogenesis [J].
Dawson, DW ;
Volpert, OV ;
Gillis, P ;
Crawford, SE ;
Xu, HJ ;
Benedict, W ;
Bouck, NP .
SCIENCE, 1999, 285 (5425) :245-248
[3]  
Duh EJ, 2002, INVEST OPHTH VIS SCI, V43, P821
[4]   Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report [J].
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, R ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Cleeman, JI ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ ;
Keller, SA ;
Jehle, AJ .
CIRCULATION, 2002, 106 (25) :3143-3421
[5]   Diagnosis and management of the metabolic syndrome - An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement [J].
Grundy, SM ;
Cleeman, JI ;
Daniels, SR ;
Donato, KA ;
Eckel, RH ;
Franklin, BA ;
Gordon, DJ ;
Krauss, RM ;
Savage, PJ ;
Smith, SC ;
Spertus, JA ;
Costa, F .
CIRCULATION, 2005, 112 (17) :2735-2752
[6]   Pigment epithelium-derived factor prevents advanced glycation end products-induced monocyte chemoattractant protein-1 production in microvascular endothelial cells by suppressing intracellular reactive oxygen species generation [J].
Inagaki, Y ;
Yamagishi, S ;
Okamoto, T ;
Takeuchi, M ;
Amano, S .
DIABETOLOGIA, 2003, 46 (02) :284-287
[7]   A proteomic approach for identification of secreted proteins during the differentiation of 3T3-L1 preadipocytes to adipocytes [J].
Kratchmarova, I ;
Kalume, DE ;
Blagoev, B ;
Scherer, PE ;
Podtelejnikov, AV ;
Molina, H ;
Bickel, PE ;
Andersen, JS ;
Fernandez, MM ;
Bunkenborg, J ;
Roepstorff, P ;
Kristiansen, K ;
Lodish, HF ;
Mann, M ;
Pandey, A .
MOLECULAR & CELLULAR PROTEOMICS, 2002, 1 (03) :213-222
[8]   WHO and ATPIII proposals for the definition of the metabolic syndrome in patients with Type 2 diabetes [J].
Marchesini, G ;
Forlani, G ;
Cerrelli, F ;
Manini, R ;
Natale, S ;
Baraldi, L ;
Ermini, G ;
Savorani, G ;
Zocchi, D ;
Melchionda, N .
DIABETIC MEDICINE, 2004, 21 (04) :383-387
[9]   Therapy insight: adipocytokines in metabolic syndrome and related cardiovascular disease [J].
Matsuzawa, Y .
NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE, 2006, 3 (01) :35-42
[10]   Renal insufficiency and heart failure - Prognostic and therapeutic implications from a prospective cohort study [J].
McAlister, FA ;
Ezekowitz, J ;
Tonelli, M ;
Armstrong, PW .
CIRCULATION, 2004, 109 (08) :1004-1009